TransMedics Group (NASDAQ:TMDX) Shares Gap Down – Time to Sell?

TransMedics Group, Inc. (NASDAQ:TMDX)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $64.22, but opened at $61.32. TransMedics Group shares last traded at $63.35, with a volume of 215,169 shares trading hands.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a research note on Tuesday, December 3rd. Robert W. Baird lowered their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a research report on Wednesday, December 11th. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. Piper Sandler decreased their target price on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Finally, Canaccord Genuity Group reduced their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $122.70.

TransMedics Group Stock Performance

The firm’s 50-day simple moving average is $91.40 and its 200-day simple moving average is $129.80. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. The company has a market capitalization of $2.04 billion, a PE ratio of 64.77 and a beta of 2.06.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period in the previous year, the firm posted ($0.12) earnings per share. The company’s revenue was up 63.7% on a year-over-year basis. On average, research analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Buying and Selling at TransMedics Group

In other news, CEO Waleed H. Hassanein sold 8,625 shares of the business’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $132.71, for a total transaction of $1,144,623.75. Following the sale, the chief executive officer now owns 61,643 shares in the company, valued at approximately $8,180,642.53. The trade was a 12.27 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Tamer I. Khayal sold 2,958 shares of the business’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the sale, the insider now owns 20,843 shares in the company, valued at approximately $3,089,766.32. The trade was a 12.43 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 19,417 shares of company stock valued at $2,240,738. 7.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors have recently bought and sold shares of the business. State of Alaska Department of Revenue purchased a new stake in shares of TransMedics Group in the 3rd quarter valued at $2,560,000. Charles Schwab Investment Management Inc. boosted its holdings in TransMedics Group by 2.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 271,694 shares of the company’s stock valued at $42,656,000 after purchasing an additional 6,634 shares during the last quarter. Zacks Investment Management acquired a new stake in TransMedics Group during the 3rd quarter worth about $1,607,000. Vaughan Nelson Investment Management L.P. raised its stake in shares of TransMedics Group by 24.3% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after buying an additional 64,360 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in shares of TransMedics Group by 665.1% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock worth $11,716,000 after buying an additional 64,872 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.